CD274 and neoplasm: In vitro studies and clinical trials have also explored the possible efficacy of novel strategies combining standard treatments with emerging therapies aimed to interrupt receptors/ligands interactions such as PD1/PD-L1 [43] or KIRs/HLA-I [44], which are capable of limiting the anti-tumor function of immune effectors.